News

Back

Stealth BioTherapeutics to Present at 28th Annual Piper Jaffray Healthcare Conference

November 28, 2016

BOSTON – November 28, 2016 – Stealth BioTherapeutics, a clinical-stage biopharmaceutical company developing investigational drugs to treat mitochondrial dysfunction, today announced that Reenie McCarthy, Chief Executive Officer of Stealth, will present a corporate overview at the 28th Annual Piper Jaffray Healthcare Conference at 9:10 a.m. ET on Tuesday, November 29, 2016 in New York City.

Stealth BioTherapeutics: Leading Mitochondrial Medicine

Stealth BioTherapeutics is a privately held biopharmaceutical company committed to bringing mitochondrial therapies to patients to treat both rare and common diseases. Stealth’s clinical development program is focused along several core therapeutic areas, including primary mitochondrial diseases, cardiorenal diseases and ophthalmic disorders. More information regarding Stealth and its pipeline is available at StealthBT.com.

Contact:

Media Relations
dna Communications
Kate Contreras
Phone: 617-520-7088
Media@StealthBT.com

Investor Relations
Stern IR
Beth DelGiacco
Phone: 212-362-1200
IR@StealthBT.com

Media Relations

dna Communications
Kate Contreras, 617-520-7088
media@stealthbt.com

Investor Inquiries
Stern IR
Lauren Stival, 212-362-1200
IR@stealthbt.com